Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab reported updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (Zoci) at the NANETS 2026 symposium. The results indicate that Zoci induces clinically meaningful responses in patients with extrapulmonary neuroendocrine carcinomas. The safety profile of Zoci is also considered manageable.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zoci shows clinically meaningful responses.
  • The safety profile is manageable.
  • Data presented at a significant medical symposium.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Cash runway
~29 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), will be shared tomorrow at the North American Neuroendocrine Tumor Society (NANETS) 2026 Multidisciplinary NET Medical Symposium in Las Vegas. The data indicate that zoci demonstrated clinically meaningf

Frequently Asked Questions

What is zocilurtatug pelitecan?

It is a DLL3-targeting antibody-drug conjugate formerly known as ZL-1310.

What cancer type does Zoci treat?

The drug targets previously treated extrapulmonary neuroendocrine carcinomas.

Where was the data presented?

Updated Phase 1b/2 trial results were shared at the NANETS 2026 symposium.

What were the trial results?

Zoci demonstrated clinically meaningful responses with a manageable safety profile.

ShareAdd on Google
Tags: ZLAB zocilurtatug neuroendocrine carcinoma clinical trial NANETS 2026
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$560M liquidity · $19M/mo burn
~29 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+48%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →